Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Bellevue Group AG

Bellevue Group AG reduced its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 52.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,740 shares of the company's stock after selling 102,974 shares during the quarter. Bellevue Group AG owned about 0.20% of Omnicell worth $4,218,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of OMCL. Algert Global LLC boosted its stake in shares of Omnicell by 25.3% during the fourth quarter. Algert Global LLC now owns 20,642 shares of the company's stock worth $919,000 after buying an additional 4,170 shares during the period. ArrowMark Colorado Holdings LLC grew its stake in shares of Omnicell by 4.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after purchasing an additional 56,117 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Omnicell by 7.4% during the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock worth $2,417,000 after purchasing an additional 3,725 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Omnicell by 277.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 21,770 shares of the company's stock worth $969,000 after purchasing an additional 16,003 shares during the period. Finally, Northern Trust Corp increased its stake in Omnicell by 14.1% in the 4th quarter. Northern Trust Corp now owns 565,026 shares of the company's stock valued at $25,155,000 after buying an additional 69,916 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Trading Down 0.7 %

NASDAQ:OMCL opened at $31.16 on Friday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $33.47 and a 200-day simple moving average of $40.46. The company has a market capitalization of $1.46 billion, a PE ratio of 115.41, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a report on Saturday. Wells Fargo & Company dropped their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Benchmark reissued a "buy" rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $50.67.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.